Business Wire

GA-CYBLE

5.4.2021 23:56:07 CEST | Business Wire | Press release

Share
Cyble Announces $4 Million in Seed Funding

Cyble, a global cyber intelligence firm specializing in providing early warning intelligence on cyber threats, announced today that it has raised a $4M seed financing round led by Blackbird Ventures and Spider Capital, with participation from Xoogler Ventures, Picus Capital, and Cathexis Ventures.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210405005474/en/

The funding comes as Cyble graduates from Y Combinator, which accepted Cyble into its Winter 2021 (W21) cohort and provided pre-seed funding in January of this year. These investments demonstrate the continued trust that investors and clients have in Cyble.

Cyble has made huge progress over the last year. "We started this company with an ambitious goal: to equip organizations with real-time visibility into vulnerabilities in the cyber landscape and help safeguard their businesses. As we continue to deliver what modern organizations need, the seed funding reaffirms our strategy and vision. It will enable Cyble to onboard resources and scale our SaaS platform, Cyble Vision, in lock step with our rapidly growing client base," says Manish Chachada, COO and Co-founder of Cyble.

Michael Neril of Spider Capital noted: “We are excited to partner with Cyble as they scale their revolutionary SaaS platform focused on dark web monitoring. The founding team have deep domain expertise in this space, and we look forward to seeing their product gain further traction in this market.”

Tom Humphrey of Blackbird Ventures noted: "The Cyble team are wild hearts on a mission. We are struck by the progress they have achieved to date and believe they are only just getting started. Dark web monitoring and mitigation capabilities are front of mind for modern organizations and the market is growing rapidly."

Cyble has also signed a partnership with Aditya Birla Group Innovation Fund to jointly identify and engage in the pilot for application and use of Cyble’s offerings at Aditya Birla Group (ABG). Headquartered in India, the Aditya Birla Group is a 150 years old multi-business, multi-national conglomerate. With 45B USD in global revenues, the ABG businesses are leaders in their respective industry spaces. “Developing a system of early warning signals for threats to corporate assets arising from the dark web is a new frontier for our cyber security and is an area of high priority for ABG. We are proud to partner with the Cyble Team to take the lead in testing, refining, adopting and co-innovating new-age cyber security technologies with them,” said Shrenik M Khasgiwala of ABG Innovation Fund.

"We're really excited about what the next 18 to 24 months hold for Cyble," says Beenu Arora, CEO and Co-founder of Cyble. "It's our mission to empower organizations to fortify against increasingly sophisticated cyber threats. We are extremely excited to welcome our new partners and have the additional resources to accelerate our product roadmap and better arm our clients with the tools they require to fight cybercrime."

About Cyble
Cyble is a global threat intelligence SaaS provider that helps enterprises protect themselves from cybercrimes and exposure in the darkweb. Cyble’s prime focus is to provide organizations with real-time visibility into their digital risk footprint. Backed by Y Combinator as part of the 2021 winter cohort, Cyble has also been recognized by Forbes as one of the top 20 Best Cybersecurity Startups To Watch In 2020. Headquartered in Alpharetta, Georgia, and with offices in Australia, Singapore, and India, Cyble has a global presence. To learn more about Cyble, visit www.cyble.io . To learn more about Cyble, visit www.cyble.io .

Link:

ClickThru

Social Media:

https://www.facebook.com/cybleau

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye